Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States.

ABSTRACT:

Background

Selected molecular biomarkers were incorporated into the US cancer registry reporting for patients with brain tumors beginning in 2018. We investigated the completeness and validity of these variables and described the epidemiology of molecularly defined brain tumor types.

Methods

Brain tumor patients with histopathologically confirmed diagnosis in 2018 were identified within the Central Brain Tumor Registry of the United States and NCI's Surveillance, Epidemiology, and End Results Incidence databases. The brain molecular markers (BMM) site-specific data item was assessed for coding completeness and validity. 1p/19q status, MGMT promoter methylation, WHO grade data items, and new ICD-O-3 codes were additionally evaluated. These data were used to profile the charac

SUBMITTER: Iorgulescu JB 

PROVIDER: S-EPMC9629432 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature